E-Learning

One quarter into 2025, CVS Health has risen the most of any stock in the S&P 500, with a share price that has popped 50% since the start of the year.

The S&P 500 gained 0.6% on Monday, March 31, boosted by an afternoon rally even as investors brace for the planned onset of reciprocal tariffs later this week.

NEW YORK (Reuters) -As Wall Street draws the curtain on a tumultuous quarter in which stocks logged a record high before tumbling into correction, investors are faced with a mountain of policy uncertainty that clouds the outlook for coming quarters. The S&P 500 Index finished the quarter down 4.6%, its worst first three months of a year since the first quarter of 2022. Investors, who started the year with high hopes for pro-growth policies from the Trump administration, have been spooked by a barrage of tariff-related headlines.

Fashion conglomerate PVH (NYSE:PVH) beat Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 4.8% year on year to $2.37 billion. Its non-GAAP profit of $3.27 per share was 1.8% above analysts’ consensus estimates.

Shares of energy drink company Celsius (NASDAQ:CELH) jumped 8.9% in the afternoon session after Truist analysts upgraded the stock's rating from Hold to Buy and raised the price target from $35 to $45. The analysts added, "In our opinion, the market is already looking past the hiccups of the legacy business in 2024 and the brand's slowdown in 1Q25."

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 12.5% in the morning session after Peter Marks, the head of the FDA's Center for Biologics Evaluation and Research (CBER), resigned on Friday, 28 March 2025. Marks noted his departure was related to "misinformation and lies" around immunization and raised concerns about the Trump administration's ability to "swiftly approve critical vaccines."

(Bloomberg) -- The Trump administration’s mixed messaging on what new tariffs will be unveiled Wednesday and how they’ll be announced have equities traders flustered as they try to position around the biggest risk confronting the market in years.Most Read from BloombergWhat Frank Lloyd Wright Learned From the DesertGold-Rush Fever Returns to Historic New Zealand Mining TownBank Regulators Fight for Desks as OCC Returns to New York Tower“The best way to summarize this trading environment is frust

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).

Shares of conservative news outlet Newsmax skyrocketed in the company’s first day of trading on the New York Stock Exchange Monday after a $75 million initial public offering.

Shares of Canada Goose Holdings set a new record low Monday after analysts from Barclays downgraded the apparel maker's stock.